Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 7
1989 10
1990 11
1991 10
1992 11
1993 12
1994 14
1995 17
1996 18
1997 10
1998 9
1999 17
2000 11
2001 21
2002 33
2003 18
2004 26
2005 34
2006 40
2007 31
2008 31
2009 34
2010 43
2011 44
2012 52
2013 57
2014 76
2015 88
2016 94
2017 94
2018 108
2019 126
2020 148
2021 162
2022 157
2023 137
2024 52

Text availability

Article attribute

Article type

Publication date

Search Results

1,636 results

Results by year

Filters applied: . Clear all
Page 1
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM, Nowakowski GS, Wang Y. Bock AM, et al. Curr Treat Options Oncol. 2022 Feb;23(2):155-170. doi: 10.1007/s11864-021-00925-1. Epub 2022 Feb 19. Curr Treat Options Oncol. 2022. PMID: 35182296 Review.
While there have been numerous advances in the field of non-Hodgkin lymphoma (NHL) over the last decade, relapsed and/or refractory (R/R) NHL remains a challenge and an area with unmet needs. ...
While there have been numerous advances in the field of non-Hodgkin lymphoma (NHL) over the last decade, relapsed and/o …
Non-Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM. Ansell SM. Mayo Clin Proc. 2015 Aug;90(8):1152-63. doi: 10.1016/j.mayocp.2015.04.025. Mayo Clin Proc. 2015. PMID: 26250731 Review.
Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and clinical behavior. ...Most patients respond well to treatment, but relapses are frequent and additional therapies including stem cell transplant are often needed. Because many subtype
Non-Hodgkin lymphomas are lymphoid malignant neoplasms with diverse biological and clinical behavior. ...Most patients respond
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. Horwitz SM, et al. J Natl Compr Canc Netw. 2022 Mar;20(3):285-308. doi: 10.6004/jnccn.2022.0015. J Natl Compr Canc Netw. 2022. PMID: 35276674
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-c …
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for a …
Epidemiology of Follicular Lymphoma.
Cerhan JR. Cerhan JR. Hematol Oncol Clin North Am. 2020 Aug;34(4):631-646. doi: 10.1016/j.hoc.2020.02.001. Epub 2020 May 5. Hematol Oncol Clin North Am. 2020. PMID: 32586570 Free PMC article. Review.
Follicular lymphoma (FL) is a common indolent lymphoma subtype in Western countries. ...
Follicular lymphoma (FL) is a common indolent lymphoma subtype in Western countries. ...
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. Zelenetz AD, et al. J Natl Compr Canc Netw. 2023 Nov;21(11):1118-1131. doi: 10.6004/jnccn.2023.0057. J Natl Compr Canc Netw. 2023. PMID: 37935098
Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory …
Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/re …
Odronextamab, a human CD20CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Bannerji R, et al. Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1. Lancet Haematol. 2022. PMID: 35366963 Free PMC article. Clinical Trial.
We aimed to evaluate the safety and antitumour activity of odronextamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. METHODS: This single-arm, multicentre, phase 1, dose-escalation and dose-expansion (ELM-1) trial was conducted at ten …
We aimed to evaluate the safety and antitumour activity of odronextamab in patients with relapsed or refractory B-cell non-Hodgkin
Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.
King RL, Hsi ED, Chan WC, Piris MA, Cook JR, Scott DW, Swerdlow SH. King RL, et al. Virchows Arch. 2023 Jan;482(1):193-205. doi: 10.1007/s00428-022-03404-6. Epub 2022 Sep 3. Virchows Arch. 2023. PMID: 36057749 Review.
Since the 2016 WHO update, progress has been made in understanding the biology of Burkitt lymphoma (BL) and the concept of high-grade B-cell lymphomas (HGBCL) that allows some degree of refinement. ...HGBCL, NOS remains a diagnosis of exclusion that should be used only in …
Since the 2016 WHO update, progress has been made in understanding the biology of Burkitt lymphoma (BL) and the concept of high-grade …
ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
Nowakowski GS, Czuczman MS. Nowakowski GS, et al. Am Soc Clin Oncol Educ Book. 2015:e449-57. doi: 10.14694/EdBook_AM.2015.35.e449. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993209 Free article. Review.
There is a substantial variability to antitumor activity by novel therapeutics because of the unique heterogeneity and biology that exists both between and within lymphoma subtypes. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Ho
There is a substantial variability to antitumor activity by novel therapeutics because of the unique heterogeneity and biology that exists b …
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
Phillips T, Chan H, Tam CS, Tedeschi A, Johnston P, Oh SY, Opat S, Eom HS, Allewelt H, Stern JC, Tan Z, Novotny W, Huang J, Trotman J. Phillips T, et al. Blood Adv. 2022 Jun 14;6(11):3472-3479. doi: 10.1182/bloodadvances.2021006083. Blood Adv. 2022. PMID: 35390135 Free PMC article. Clinical Trial.
Outcomes for marginal zone lymphoma (MZL) and follicular lymphoma (FL) remain suboptimal, owing to the limited number of approved agents and the incurable nature of the diseases. ...Response was assessed by an independent review committee for MZL and the investigato …
Outcomes for marginal zone lymphoma (MZL) and follicular lymphoma (FL) remain suboptimal, owing to the limited number of appro …
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. Zelenetz AD, et al. J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230. doi: 10.6004/jnccn.2021.0054. J Natl Compr Canc Netw. 2021. PMID: 34781267
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug co …
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the d …
1,636 results